<DOC>
<DOCNO>
EP-0003382
</DOCNO>
<TEXT>
<DATE>
19790808
</DATE>
<IPC-CLASSIFICATIONS>
A61K-9/08 <main>A61K-9/00</main> A61K-47/20 A61K-47/14 
</IPC-CLASSIFICATIONS>
<TITLE>
solvent vehicle for therapeutics and pharmaceutical composition containing it.
</TITLE>
<APPLICANT>
acf chemiefarma nvnl<sep>acf chemiefarma nv<sep>acf chemiefarma nvpostbus 5nl-3600 aa maarssennl<sep>acf chemiefarma nv<sep>
</APPLICANT>
<INVENTOR>
ladage cornelis adrianus drs<sep>van linge douwe jan drs<sep>van riessen huibert adriaan dr<sep>ladage, cornelis adrianus, drs.<sep>van linge, douwe jan, drs.<sep>van riessen, huibert adriaan, drs.<sep>ladage, cornelis adrianus, drs.mereveldlaan 147nl-3454 ce de meernnl<sep>van linge, douwe jan, drs.molenweg 2bnl-3755 bd eemnesnl<sep>van riessen, huibert adriaan, drs.kastanjelaan 27nl-6741 dt lunterennl<sep>ladage, cornelis adrianus, drs. <sep>van linge, douwe jan, drs.<sep>van riessen, huibert adriaan, drs.  <sep>ladage, cornelis adrianus, drs.mereveldlaan 147nl-3454 ce de meernnl<sep>van linge, douwe jan, drs.molenweg 2bnl-3755 bd eemnesnl<sep>van riessen, huibert adriaan, drs.kastanjelaan 27nl-6741 dt lunterennl<sep>
</INVENTOR>
<ABSTRACT>
the invention relates to a solvent vehicle for therapeutics  comprising a dialkyl ester of adipic acid and, optionally,  dmsc, which is particularly useful for therapeutic materials  having a low solubility or being insoluble in water.  the invention further relates to pharmaceutical compositions  which are suitable for parental administration,  especially by intramuscular injection, comprising a therapeutically  active material dissolved in said solvent vehicle.  solvent vehicles containing di-n-butyl adipate and  dmso, and, if desired, one or more adjuvants, are preferred.  particularly useful are pharmaceutical compositions for  the prophylaxis and or treatment of diseases caused by  internal parasites, which can be administered by intramuscular  injection.  a preferred embodiment of the invention is an  injectable composition against distomatosis (liver fluke  disease) containing proportionally 12. 5 g 4,6′-dichloro-4′,6-­ dinitro-2,2′-methylene-diphenol and 30 g of dmso, completed  with di-n-butyl adipate to 100 cm³.  
</ABSTRACT>
</TEXT>
</DOC>
